WO2026018066 - HDAC-6 INHIBITING COMPOUNDS AND TREATMENT OF DISEASES WITH THE SAME
National phase entry is expected:
Publication Number
WO/2026/018066
Publication Date
22.01.2026
International Application No.
PCT/IB2025/000366
International Filing Date
17.07.2025
Title **
[English]
HDAC-6 INHIBITING COMPOUNDS AND TREATMENT OF DISEASES WITH THE SAME
[French]
COMPOSÉS INHIBITEURS DE HDAC-6 ET TRAITEMENT DE MALADIES AVEC CEUX-CI
Applicants **
EUROFARMA LABORATÓRIOS S.A.
UNIVERSIDADE FEDERAL DO RIO DE JANEIRO
Inventors
BARREIRO, Gabriela
MONTEIRO, Júlia, Lammoglia
REINA GAMBA, Luis, Eduardo
LIMA, Lidia, Moreira
Priority Data
63/673,074
18.07.2024
US
63/717,423
07.11.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 16242 | |
| EPO | Filing, Examination, Granting | 111402 | |
| Japan | Filing, Examination, Granting | 4612 | |
| South Korea | Filing, Examination, Granting | 7195 | |
| USA | Filing, Examination, Granting | 33910 |
Total:
173,361
Contact Us
Abstract[English]
The present invention provides histone deacetylase 6 (HDAC6) inhibitors. The compounds provided in the present invention may be useful for methods of treating or preventing diseases or conditions associated with HDAC6,[French]
La présente invention concerne des inhibiteurs de l'histone désacétylase 6 (HDAC6). Les composés fournis dans la présente invention peuvent être utiles pour des méthodes de traitement ou de prévention de maladies ou d'états associés à HDAC6.